RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Procept Biorobotics Stock

Procept Biorobotics P/E 2024

Procept Biorobotics P/E

-32.36

Ticker

PRCT

ISIN

US74276L1052

As of Dec 17, 2024, Procept Biorobotics's P/E ratio was -32.36, a 123.17% change from the -14.5 P/E ratio recorded in the previous year.

The Procept Biorobotics P/E history

Procept Biorobotics Aktienanalyse

What does Procept Biorobotics do?

PROCEPT BioRobotics Corp (PROCEPT) is a California-based medical technology company specializing in the development of robotic technologies for urological surgery. History: PROCEPT was founded in 2013 by Dr. Chin and his group at Johns Hopkins University School of Medicine. They developed a novel technology that had the potential to revolutionize the treatment of prostate cancer. PROCEPT used a robust Intuitive Surgical platform and developed a novel tissue classification technology that allows surgeons to operate with accuracy and safety. The first system, called AquaBeam®, was approved by the US Food and Drug Administration (FDA) in 2018 and has since been in use in Europe and the US. Business: PROCEPT aims to improve urological surgery through the use of robotic technologies, thereby increasing patient safety and care. The company focuses on the development and commercialization of robotic systems for the treatment of prostate cancer and other urological diseases. Products: PROCEPT has developed Aquablation®, a robotic system for the treatment of prostate cancer. It is a minimally invasive technology that uses high-precision waterjet cutting (accuracy reduced to millimeters) to remove cancerous tissue quickly, effectively, and accurately. The technology can also be used in surgical procedures on the bladder, urethra, and other urological organs. Divisions: PROCEPT has a broad portfolio of services and products in the field of urological surgery. The AquaBeam® technology is the first system developed to treat malignant prostate tumors using robotic technologies. The technology is used in hospitals, clinics, and medical facilities worldwide. In addition, PROCEPT offers training and support for surgeons and medical personnel. Conclusion: PROCEPT BioRobotics Corp is an emerging medical technology company specializing in robotics-based urological surgery. The AquaBeam® technology is an innovative, robotic technology for the treatment of prostate cancer. The company is on its way to revolutionizing urological surgery and making a significant contribution to improving healthcare. Procept Biorobotics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Procept Biorobotics's P/E Ratio

The Price to Earnings (P/E) Ratio of Procept Biorobotics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Procept Biorobotics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Procept Biorobotics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Procept Biorobotics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Procept Biorobotics stock

What is the price-to-earnings ratio of Procept Biorobotics?

The price-earnings ratio of Procept Biorobotics is currently -32.36.

How has the price-earnings ratio of Procept Biorobotics changed compared to last year?

The price-to-earnings ratio of Procept Biorobotics has increased by 123.17% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Procept Biorobotics high compared to other companies?

Yes, the price-to-earnings ratio of Procept Biorobotics is high compared to other companies.

How does an increase in the price-earnings ratio of Procept Biorobotics affect the company?

An increase in the price-earnings ratio of Procept Biorobotics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Procept Biorobotics affect the company?

A decrease in the price-earnings ratio of Procept Biorobotics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Procept Biorobotics?

Some factors that influence the price-earnings ratio of Procept Biorobotics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Procept Biorobotics pay?

Over the past 12 months, Procept Biorobotics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Procept Biorobotics is expected to pay a dividend of 0 USD.

What is the dividend yield of Procept Biorobotics?

The current dividend yield of Procept Biorobotics is .

When does Procept Biorobotics pay dividends?

Procept Biorobotics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Procept Biorobotics?

Procept Biorobotics paid dividends every year for the past 0 years.

What is the dividend of Procept Biorobotics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Procept Biorobotics located?

Procept Biorobotics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Procept Biorobotics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Procept Biorobotics from 12/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/17/2024.

When did Procept Biorobotics pay the last dividend?

The last dividend was paid out on 12/17/2024.

What was the dividend of Procept Biorobotics in the year 2023?

In the year 2023, Procept Biorobotics distributed 0 USD as dividends.

In which currency does Procept Biorobotics pay out the dividend?

The dividends of Procept Biorobotics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Procept Biorobotics

Our stock analysis for Procept Biorobotics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Procept Biorobotics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.